About risankizumab
Interleukin-23 inhibitor biologic
Used for
- Treats moderate-to-severe plaque psoriasis in adults and children aged 6 years and older.
- Treats active psoriatic arthritis in adults.
- Treats Crohn’s disease and ulcerative colitis in adults.
Usual adult dose
Plaque psoriasis or psoriatic arthritis: 150 mg under the skin at weeks 0 and 4, then every 12 weeks. Bowel disease uses different intravenous induction and maintenance schedules.
Usual dose in children
For plaque psoriasis in children aged 6 years and older, dosing depends on body weight; given under the skin at weeks 0 and 4, then every 12 weeks.
Common side effects
- Upper respiratory infections
- Headache
- Fatigue
- Injection-site reactions
Important warnings
- Check for tuberculosis before treatment; active tuberculosis must be treated first.
- Do not start during a serious infection; seek assessment for infection symptoms.
- Avoid live vaccines during treatment.
- Monitor for allergic reactions, including severe reactions.
Pregnancy
Human pregnancy information is limited. Use only when the expected benefit justifies potential fetal risk.
Breastfeeding
It is unknown whether risankizumab passes into human milk; discuss potential infant exposure with a healthcare professional.
Interactions
- Live vaccines may cause infection and should be avoided.
- Other immune-suppressing medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.